8-K: Scilex Holding Company Adjusts Director Compensation Policy Following Reverse Stock Split

Scilex Holding Company amends its non-employee director compensation policy to reflect a 1-for-35 reverse stock split, adjusting equity grants accordingly.

Summary

• Scilex Holding Company has amended its Non-Employee Director Compensation Policy following a 1-for-35 reverse stock split that was completed on April 15, 2025.
• The Compensation Committee approved the changes on May 9, 2025.
• The adjustments affect the initial and annual stock option grants for non-employee directors.
• Newly appointed or elected non-employee directors will now receive an initial option grant to purchase 7,142 shares of Common Stock.
• Continuing non-employee directors will be eligible for an annual stock option grant to purchase 2,857 shares of Common Stock.
• All other aspects of cash and equity compensation remain unchanged.
• Annual cash compensation for board members is $82,500.
• Chairs of certain committees receive an additional $37,500, while other committee members receive an additional $15,000.
• Equity compensation vests monthly over 48 months for initial grants and 12 months for annual grants, subject to continued service.
• The company will reimburse reasonable travel expenses for directors attending board and committee meetings.

Sentiment

Score: 7

Explanation: The document reflects a routine adjustment to director compensation following a reverse stock split, indicating stable corporate governance. The sentiment is neutral to slightly positive as it ensures continued alignment of director interests with shareholders.

Positives

• The adjustments to the compensation policy ensure that non-employee directors' equity compensation remains aligned with the company's performance after the reverse stock split.
• The policy provides clear guidelines for cash and equity compensation for non-employee directors.
• Reimbursement of travel expenses supports director attendance at important meetings.

Future Outlook

The document does not contain specific forward-looking statements beyond the implementation of the amended compensation policy.

Industry Context

Adjusting director compensation following a reverse stock split is a common practice to maintain equity incentives and alignment with company performance. This ensures that directors' interests remain tied to the long-term success of the company.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical and biotech industries, depending on company size, stage of development, and board responsibilities.
• Cash compensation for board members at similar-sized companies typically ranges from $50,000 to $150,000 annually, with additional compensation for committee roles.
• Equity grants are also common, with the number of shares or options varying based on company valuation and individual director contributions.
• For example, a company like Sorrento Therapeutics (parent company of Scilex) might have a similar compensation structure for its directors, although the specific amounts and equity grants could differ based on their respective board policies and company performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The adjusted compensation policy aims to align director interests with shareholder value.
• Directors: The policy outlines the compensation structure for non-employee directors, ensuring fair remuneration for their services.

Key Dates

Keywords

Non-Employee Director Compensation, Reverse Stock Split, Equity Compensation, Stock Options, Scilex Holding Company, Compensation Policy, Corporate Governance